Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Szczepańska, Anna" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    Progressive forms of multiple sclerosis: disease-modifying therapy review
    Autorzy:
    Sapko, Klaudia
    Szczepańska-Szerej, Anna
    Jamroz-Wiśniewska, Anna
    Kulczyński, Marcin
    Marciniec, Michał
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1167060.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Disease-modifying drugs
    Multiple sclerosis
    New therapy
    Primary-progressive MS
    Secondary-progressive MS
    Opis:
    Multiple sclerosis (MS) is a demyelinating, inflammatory, autoimmune disease of the central nervous system which affects most commonly young adults. It has wide spectrum of clinical and radiological presentations with relapses or steady progression. Recent years have brought new reports on the pathogenesis of MS. This systematized the current MS classification and created new parameters describing the course of the disease, such as activity and progression. Attention has been paid to the need for new drugs that focus on the treatment of progressive MS. Until now, the primary and secondary progressive MS have been somewhat forgotten, and most of modifying-disease drugs have been registered in the treatment of relapsing-remitting subtype. In recent years, not only new drug has been registered for the treatment of progressive MS (ocrelizumab) and another one is planned to be approved soon (siponimod), but also indications of old medicines (interferon-beta1b, cladribine, mitoxantrone, cyclophosphamide, azathioprine) have been extended. Despite intensive development, there is still a great need to seek new drugs that will stop the progression of disability in MS patients.
    Źródło:
    World Scientific News; 2018, 105; 157-167
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prevention of seizures after ischemic stroke: association between statin use and the risk of seizures
    Autorzy:
    Marciniec, Michał
    Popek-Marciniec, Sylwia
    Kulczyński, Marcin
    Pasterczyk, Katarzyna
    Szczepańska-Szerej, Anna
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1177817.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    HMG-CoA reductase inhibitor
    Post-stroke seizure
    epilepsy
    ischemic stroke
    rt-PA
    statin
    Opis:
    More than 50 million people worldwide suffer from epilepsy. In approximately 50% cases of newly diagnosed patients over 60 years of age seizures are related to stroke. Post-stroke lesions in brain tissue may result in 7 fold increase risk of seizures compared to the general population. The most significant risk factors for post-stroke seizures (PSS) and post-stroke epilepsy (PSE) include stroke severity, intracerebral or subarachnoid hemorrhage and cortical involvement. Increased incidence of PSS was also observed in younger patients especially with previous early PSS occurrence. Statins (HMG-CoA reductase inhibitors) are a class of lipid-lowering medications characterized by neuroprotective and antiepileptic effects. The main result of the performed studies was significantly reduced risk of developing PSS associated with a post-stroke, but not pre-stroke statin use. Moderate to high doses of statin and early administration in acute phase of stroke potentiated the beneficial effects of the treatment. The evidences for the association between PSS prevention and statin treatment become more significant, however the most recent AHA/ASA recommendations do not include any medications in the PSS prophylaxis. This article summarizes the current knowledge about the prediction and prevention of PSS and PSE.
    Źródło:
    World Scientific News; 2018, 99; 181-192
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The comparison of tenecteplase and alteplase in acute stroke treatment: meta-analysis of 5 randomized clinical trials
    Autorzy:
    Marciniec, Michał
    Szczepańska-Szerej, Anna
    Kulczyński, Marcin
    Popek-Marciniec, Sylwia
    Wyjadłowska, Karolina
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1177755.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    alteplase
    cerebral infarction
    ischemic stroke
    rt-PA
    tenecteplase
    thrombolysis
    Opis:
    Thrombolysis with the use of intravenously administrated alteplase is the only approved thrombolytic treatment of acute ischemic stroke. Tenecteplase is a fibrinolytic protein bioengineered from human tissue plasminogen activator with higher fibrin specificity, enhanced affinity to fibrin-rich clots, faster clot lysis and prolonged plasma half-life. The aim of this study was to determine which thrombolytic therapy (tenecteplase versus alteplase) provides better efficacy and safety outcomes. Eligible studies for meta-analysis published from their inception to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: ClinicalTrials.gov and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Five studies comprising 1529 patients were included. Tenecteplase 0,25mg/kg administration resulted in significantly higher number of patients with excellent score (0-1) in modified Rankin Scale at 90 days compared to alteplase group (RR 1,30, p=0,0215, 95% CI 1,04–1,62). Additionally, more patients treated with tenecteplase 0,25 mg/kg tended to develop favorable score changes in NIHSS at 24 hours after stroke onset (>8 point improvement, scale quantifying stroke severity) compared to alteplase treatment (RR 1,60, p=0,0545, 95% CI 0,99–2,58). No above correlation were observed in higher dose of tenecteplase group (0,4 mg/kg). There were no significant differences in the frequency of symptomatic intracerebral hemorrhage (ICH) and the mortality rates within 90 days after stroke onset in comparison of tenecteplase and alteplase groups. Tenecteplase 0,25 mg/kg administration in acute ischemic stroke resulted in better functional outcome at 90 days after ischemic stroke onset and tended to restrict the severity of stroke at 24 hours in NIHSS compared to alteplase 0,9 mg/kg. The frequency of symptomatic ICH occurrence and mortality within 3 months between tenecteplase and alteplase were comparable.
    Źródło:
    World Scientific News; 2018, 100; 61-73
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The effectiveness of patent foramen ovale closure and antiplatelet or anticoagulant therapies for cryptogenic ischemic stroke
    Autorzy:
    Marciniec, Michał
    Szczepańska-Szerej, Anna
    Kulczyński, Marcin
    Popek-Marciniec, Sylwia
    Pasterczyk, Katarzyna
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1177466.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Anticoagulation Agents
    Antiplatelet Agents
    Cerebral Infarction
    Cerebrovascular Stroke
    Patent Foramen Ovale
    Opis:
    Patent foramen ovale (PFO) occurs in approximately 50% cryptogenic strokes cases. One of the most clinically important consequences of PFO is paradoxical embolization of venous thrombus resulting in recurrent stroke. The aim of this meta-analysis is to compare the efficacy and safety of PFO closure and antiplatelet or anticoagulant therapy alone (medical therapy, MT) in the secondary stroke prevention. Eligible studies for meta-analysis published from May 2008 to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: ClinicalTrials.gov and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Three studies comprising 2’307 patients were included. The main outcomes were: recurrent stroke occurrence during follow-up period, the frequency of serious adverse events (SAE) and the mortality rate. Statistical significance was found in the assessment of recurrent stroke occurrence when the comparison referred to PFO closure and antiplatelet therapy (RR 0,30, p < 0,05, 95% CI 0,11 – 0,85). There were no significant differences between PFO closure and MT in the frequency of SAE occurrence (RR 1,03, p = 0,73) and mortality rates (RR 0,69, p = 0,39). Current clinical data indicate that PFO closure devices applied to the carefully selected group of young and middle-aged patients with cryptogenic ischemic stroke may be as or more effective than antiplatelet therapy.
    Źródło:
    World Scientific News; 2018, 102; 47-58
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies